NCT06119529 is a Phase 1 clinical trial of LY3872386 in Healthy, sponsored by Eli Lilly and Company.

Who is sponsoring NCT06119529?

NCT06119529 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT06119529?

Interventions in NCT06119529: LY3872386, Prednisone, Placebo.

What condition does NCT06119529 study?

NCT06119529 studies Healthy, Atopic Dermatitis.

Is NCT06119529 still recruiting?

NCT06119529 is currently terminated. Last updated 3 October 2025.

Are results published for NCT06119529?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-10-03 · How we verify

NCT06119529

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis

Terminated Phase 1 Results posted Last updated 3 October 2025

What this trial tests

Phase 1 trial testing LY3872386 in Healthy in 18 participants. Terminated before completion.

Timeline

1 November 2023

Primary endpoint
8 April 2024

8 April 2024

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	18
Start date	1 November 2023
Primary completion	8 April 2024
Estimated completion	8 April 2024
Sites	2 locations across United States

Drugs / interventions tested

LY3872386 — full drug profile →
Prednisone (prednisone) — full drug profile →
Placebo

Conditions studied

Healthy — all drugs for Healthy →
Atopic Dermatitis — all drugs for Atopic Dermatitis →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

Adults 18 to 65, any sex, with Healthy or Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Part A: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs) and Other Non-serious Adverse Events (AEs) Considered by the Investigator to be Related to Study Drug Administration Primary · Baseline through Day 85

A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is located in the Reported Adverse Event module. Drug related TEAEs are any untoward medical occurrences that either occurs postdose or presents prior to dosing yet becomes more severe postdose, and in the opinion of the investigator is possibly related to study drug.

TEAEs

Group	Value	95% CI
Part A: Low Dose LY3872386	0
Part A: Mid-dose LY3872386	2
Part A: High Dose LY3872386	0
Part A: Placebo IV	0

SAEs

Group	Value	95% CI
Part A: Low Dose LY3872386	0
Part A: Mid-dose LY3872386	0
Part A: High Dose LY3872386	0
Part A: Placebo IV	0

AEs

Group	Value	95% CI
Part A: Low Dose LY3872386	0
Part A: Mid-dose LY3872386	2
Part A: High Dose LY3872386	0
Part A: Placebo IV	0

Pharmacokinetics (PK): Part A and B: Maximum Observed Concentration (Cmax) of LY3872386 Secondary · Day 1: predose, end of infusion, 3 hours, 6 hours, and 12 hours postdose, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose (Part A)

Cmax of LY3872386 is reported.

Group	Value	95% CI
Part A: Low Dose LY3872386	2.54	± 16.9
Part A: Mid-dose LY3872386	7.89	± 16.3
Part A: High Dose LY3872386	NA	± NA

PK: Part A and B: Area Under the Concentration Versus Time Curve (AUC) of LY3872386 Secondary · Day 1: predose, end of infusion, 3 hours, 6 hours, and 12 hours postdose, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose (Part A)

Area Under the Concentration Versus Time Curve from Time Zero to tlast (AUC\[0-tlast\]) and Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC\[0-inf\]) of LY3872386 is reported.

AUC(0-tlast) of LY3872386

Group	Value	95% CI
Part A: Low Dose LY3872386	55.7	± 15.6
Part A: Mid-dose LY3872386	328	± 19.7
Part A: High Dose LY3872386	NA	± NA

AUC(0-∞) of LY3872386

Group	Value	95% CI
Part A: Low Dose LY3872386	65.8	± 18.6
Part A: Mid-dose LY3872386	337	± 20.3
Part A: High Dose LY3872386	NA	± NA

Adverse events — posted to ClinicalTrials.gov

Time frame: Baseline up to Day 85. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Part A: Low Dose LY3872386

Serious: 0/6 (0%)

Deaths: 0/6

Part A: Mid-dose LY3872386

Serious: 0/6 (0%)

Deaths: 0/6

Part A: High Dose LY3872386

Serious: 0/1 (0%)

Deaths: 0/1

Part A: Placebo

Serious: 0/5 (0%)

Deaths: 0/5

Other adverse events (6 terms — click to expand)

Reaction	System	Part A: Low Dose LY3872386	Part A: Mid-dose LY3872386	Part A: High Dose LY3872386	Part A: Placebo
Upper respiratory tract infection	Infections and infestations	—	—	—	—
Conjunctival haemorrhage	Eye disorders	—	—	—	—
Keratitis	Eye disorders	—	—	—	—
Injection site erythema	General disorders	—	—	—	—
Headache	Nervous system disorders	—	—	—	—
Menstruation irregular	Reproductive system and breast disorders	—	—	—	—

Data from ClinicalTrials.gov NCT06119529 adverse events section.

Sponsor's own description

The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatitis. The safety of prednisone is also evaluated in healthy participants. Blood tests will be performed to investigate how the body processes the LY3872386 following single and multiple dosing in healthy participants and participants with atopic dermatitis. Blood tests will also be performed to investigate how the body processes the prednisone in healthy participants. The study is conducted in three parts (part A, B and C). The study will last up to approximately 85, 183 and 44 days for parts A, B, and C, respectively.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06119529 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 3 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06119529.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing